Collaboration Revenue, License, Upfront Payment

No definition available.

Name:	prta_CollaborationRevenueLicenseUpfrontPayment
Namespace Prefix:	prta_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

[Line Items] for License Agreement [Table]

+ References

No definition available.

+ Details

Name:	prta_LicenseAgreementLineItems
Namespace Prefix:	prta_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement, Potential Alternative Commercial Sales Milestones

+ References

No definition available.

+ Details

Name:	prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones
Namespace Prefix:	prta_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement, Potential Payment Upon Achievement of Development, Regulatory and Various First Commercial Sales Milestones

+ References

No definition available.

+ Details

Name:	prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones
Namespace Prefix:	prta_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement, Potential Payment for Achievement of non U.S. Commercial Sales Milestones

+ References

No definition available.

+ Details

Name:	prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones
Namespace Prefix:	prta_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Licensing Agreement, Cost Allocation, Percentage

+ References

No definition available.

+ Details

Name:	prta_LicensingAgreementCostAllocationPercentage
Namespace Prefix:	prta_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Licensing Agreement, Portion of Revenue and Expenses Attributable to Company, Percentage

+ References

No definition available.

+ Details

Name:	prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage
Namespace Prefix:	prta_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone Achievement, Clinical Milestone -recognized where milestone was achieved at the end of the period presented.

+ References

No definition available.

+ Details

Name:	prta_MilestoneAchievementClinicalMilestone
Namespace Prefix:	prta_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone Payment Received, Clinical Milestone

+ References

No definition available.

+ Details

Name:	prta_MilestonePaymentReceivedClinicalMilestone
Namespace Prefix:	prta_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=prta_RocheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=prta_CollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Agreements - Roche License Agreement (Details) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended		6 Months Ended
	May 05, 2021	Jun. 30, 2017	May 31, 2014	Feb. 28, 2014	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
License Agreement [Line Items]
Collaboration revenue					$ 4,420	$ 132,014	$ 7,248	$ 132,064
Collaborative Arrangement
License Agreement [Line Items]
Portion of revenue and expenses attributable to company, Percentage							30.00%
Roche
License Agreement [Line Items]
Revenue, Remaining performance obligation, Amount					0		$ 0		$ 0
Roche \| Collaborative Arrangement
License Agreement [Line Items]
Upfront payment pursuant to license agreement				$ 30,000
Milestone payment received, Clinical milestone			$ 15,000
Milestone achievement, Clinical milestone	$ 60,000	$ 30,000
Potential payment upon achievement of development, regulatory and various first commercial sales milestones							290,000
Potential payment for achievement of non U.S. commercial sales milestones							$ 175,000
License agreement, Cost allocation, Percentage							100.00%
Portion of revenue and expenses attributable to company, Percentage							70.00%
Potential Payment for US Commercial Sales Milestones							$ 155,000
Collaboration revenue
License Agreement [Line Items]
Collaboration revenue					$ 4,420	$ 132,014	$ 7,198	$ 132,014